Table 2.
Pregnancy outcomes (proportion of adverse outcome to number of exposed pregnancies) of included studies
| Outcomes Group | preterm delivery | low birth weight | spontaneous abortion | congenital malformations | ||||
|---|---|---|---|---|---|---|---|---|
| A | B | A | B | A | B | A | B | |
| Kiely CJ [17] | 2/21 | 2/21 | 0/10 | 1/11a | 0/21 | |||
| Schnitzler F [18] | 8/42 | 6/42 | 6/35 | 1/7 | 0/35 | 1/7 | ||
| Seirafi M [19] | 1/86 | 0/42 | ||||||
| Casanova MJ [20] | 0/20 | 1/9 | ||||||
| Julsgaard M [21] | 3/80 | 6/80 | 2/44 | 1/36 | ||||
| Arsenescu R [22] | 1/8 | 0/2 | 0/10 | |||||
| Slama W [23] | 1/122 | 1/64 | 3/122 | 1/64 | ||||
| Zelinkova Z [24] | 1/18 | 2/13 | 1/18 | 0/13 | ||||
A: exposed to Infliximab B: exposed to Adalimumab
aThis patient underwent an emergency colectomy following failed treatment with adalimumab. The stillbirth occurred at week 21 gestation, 11 days following the colectomy